Zhang et al. studied the therapeutic effects of crizotinib and its association with a MEK inhibitor (trametinib) or with low-dose metronomic (LDM) (low dosage of a drug administered daily) topotecan in preclinical NB models bearing the ALKF1174L mutation. Here, MAP2K7 is linked to neuroblastoma.